Sanofi’s Admelog (insulin lispro) is approved in type 1 and type 2 diabetes as a follow-on drug to Humalog, a rapid-acting insulin that is Lilly’s top selling drug, bringing in almost $700 ...

Sanofi’s Admelog (insulin lispro) is approved in type 1 and type 2 diabetes as a follow-on drug to Humalog, a rapid-acting insulin that is Lilly’s top selling drug, bringing in almost $700 ...

President and CEO Ned McCoy shared with Becker's some of the company's key objectives for the year, including the launch of some of the first medications from its Petersburg, Va.-based plant, the ...

The US Food and Drug Administration approved the first-ever rapid-acting insulin for reducing blood sugar levels. It calls the new drug “Merilog,” a biosimilar to the widely-used insulin ...

Feb. 20, 2025 -- The FDA has approved a new fast-acting insulin biosimilar to help manage blood sugar in people with diabetes, including children and adults. The product, called Merilog ...

WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) recently approved Merilog (insulin-aspart-szjj) as the first rapid-acting insulin biosimilar to Novolog (insulin aspart).

(RTTNews) - The U.S. Food and Drug Administration announced that Sanofi-Aventis U.S. LLC's Merilog (insulin-aspart-szjj) becomes the first rapid-acting insulin biosimilar product to get its ...

Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA. As a rapid-acting insulin, Merilog helps to lower mealtime blood sugar ...